Ketamine is not an SSRI. The two drugs work through entirely different chemical systems in the brain, produce effects on different timelines, and are prescribed for different situations. The confusion is understandable since both are used to treat depression, but that’s where the similarities end.
How SSRIs Work
SSRIs (selective serotonin reuptake inhibitors) target serotonin, a chemical messenger involved in mood regulation. Normally, after serotonin carries a signal between brain cells, it gets reabsorbed back into the cell that released it. SSRIs block that reabsorption, leaving more serotonin available in the gap between cells to keep passing messages. This gradual buildup of serotonin is why SSRIs take 2 to 4 weeks before you feel any real change in your mood. Common SSRIs include fluoxetine (Prozac), sertraline (Zoloft), and escitalopram (Lexapro), and they’re typically taken as a daily oral pill.
How Ketamine Works
Ketamine targets a completely different neurotransmitter system: glutamate, the brain’s primary excitatory chemical messenger. Specifically, ketamine blocks a receptor called the NMDA receptor. This blockade triggers a surge of glutamate release, which then activates a separate set of receptors that kick off a chain of events promoting the growth of new connections between brain cells, particularly in the prefrontal cortex, the region most involved in mood, decision-making, and emotional regulation.
This process also stimulates the release of a protein called BDNF (brain-derived neurotrophic factor), which essentially acts as fertilizer for neurons, helping them sprout new branches and form stronger connections. Depression is associated with a loss of these connections, and ketamine appears to rapidly rebuild them. Research published in ScienceDirect found that ketamine enhances the formation of new dendritic spines (the tiny protrusions where brain cells receive signals) on a timeline that matches the onset of its antidepressant effects.
The speed difference is dramatic. A landmark study published in Biological Psychiatry in 2000 showed that a single sub-anesthetic dose of ketamine could produce antidepressant effects within hours, with benefits lasting up to 3 days. Compare that to the weeks-long wait for SSRIs.
Different Conditions, Different Patients
SSRIs are a first-line treatment for depression and anxiety. Most people who are diagnosed with major depressive disorder will try one or more SSRIs before anything else. Ketamine occupies a very different place in the treatment landscape. It’s primarily used for treatment-resistant depression, which is defined as failing to improve after at least two adequate trials of different antidepressants.
An FDA-approved nasal spray form called esketamine (brand name Spravato) is now cleared for both treatment-resistant depression and, more recently, as a standalone treatment for major depressive disorder. However, it can only be administered in a certified healthcare setting under supervision due to its potential side effects, including dissociation, sedation, and changes in blood pressure. You can’t pick it up at a pharmacy and take it at home the way you would an SSRI.
Intravenous ketamine, the form used in many ketamine clinics, is not FDA-approved specifically for depression but is used off-label. The typical IV dose ranges from 0.2 to 0.5 mg/kg of body weight, administered over about 40 minutes in a clinical setting.
How Effective Is Ketamine for Resistant Depression?
The results for people who haven’t responded to standard antidepressants are striking. A multi-site study called Bio-K, conducted across clinics in Michigan, Maryland, and Minnesota, enrolled 74 people who had failed at least two antidepressant medications after eight or more weeks each (or had not responded to electroconvulsive therapy). After just three ketamine infusions over 11 days, 52% achieved full remission. Another 15% had a meaningful partial response, bringing the overall response rate to 67%.
These are people for whom SSRIs and other standard treatments had already failed, which makes those numbers particularly significant.
Why They’re Often Discussed Together
Both ketamine and SSRIs treat depression, so they naturally come up in the same conversations. And ketamine’s rise as a treatment option is directly tied to the shortcomings of SSRIs: slow onset, high rates of non-response, and limited effectiveness for severe cases. Standard antidepressants including SSRIs, tricyclics, and MAO inhibitors all share these limitations to varying degrees.
Ketamine represents a fundamentally different approach. Rather than tweaking serotonin levels over weeks, it floods the glutamate system, rapidly stimulates the growth of new neural connections, and produces measurable mood improvements in hours. The two drugs aren’t in the same pharmacological class, don’t affect the same brain chemicals, and aren’t interchangeable in clinical practice. Ketamine is not an SSRI, and it doesn’t work like one.